ClinicalTrials.Veeva

Menu

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

Chinese Academy of Medical Sciences & Peking Union Medical College logo

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase

Enrolling
Phase 1

Conditions

Patients With Advanced Solid Tumors

Treatments

Biological: human single chain IL-12 mRNA-single dose
Biological: human single chain IL-12 mRNA-multiple dose

Study type

Interventional

Funder types

Other

Identifiers

NCT05392699
ABOD2011-001

Details and patient eligibility

About

Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.

The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. 18 years and older.
  2. Understand and voluntarily sign the informed consent form (ICF).
  3. Histopathologically confirmed recurrent or metastatic solid tumors.
  4. Failure of prior systemic standard of care, or intolerance to severe toxicity, or lack of standard of care.
  5. Presence of at least one measurable lesion as assessed by RECIST Version 1.1.
  6. At least one superficial or deep lesion for intratumoral administration and biopsy.
  7. Sufficient organ functions.
  8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
  9. Weight > 30 kg.
  10. Expected survival longer than 12 weeks.
  11. Evidence of menopause in female patients, or for women of childbearing potential: negative for urine or blood pregnancy.

Exclusion criteria

  1. Any systemic anti-tumor therapy, within 28 days prior to the first dose.
  2. Radiotherapy within 14 days prior to first dose.
  3. Use of immunosuppressants.
  4. Major surgery within 28 days.
  5. Inadequately controlled diseases.
  6. Active autoimmune and inflammatory diseases.
  7. Clinically symptomatic central nervous system tumors or metastases.
  8. Toxicity of prior anti-tumor therapy is still NCI-CTCAE ≥ 2.
  9. Other malignancies within the previous 5 years with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
  10. Active infections.
  11. Other conditions that may increase the risk associated with the study drug, or affect the study compliance, etc., which, in the opinion of the investigator, are not suitable for participation in the study.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Human single chain IL-12 mRNA-single dose
Experimental group
Description:
Human single chain IL-12 mRNA-single dose
Treatment:
Biological: human single chain IL-12 mRNA-single dose
Human single chain IL-12 mRNA-multiple dose
Experimental group
Description:
Human single chain IL-12 mRNA-multiple dose
Treatment:
Biological: human single chain IL-12 mRNA-multiple dose

Trial contacts and locations

1

Loading...

Central trial contact

Dawei Wu, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems